Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-102 in Advanced Solid Tumors
NCT05824975Phase 2Recruiting
- Sponsor
- GI Innovation
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of GI-101A in solid tumor (advanced stage), metastatic solid tumor, soft tissue sarcoma (STS), ovarian cancer, hepatocellular carcinoma (HCC), sponsored by GI Innovation. Started May 2023; status: recruiting.
02
Drugs
GI-101A
03
Conditions
solid tumor (advanced stage)metastatic solid tumorsoft tissue sarcoma (STS)ovarian cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05824975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824975.